Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Similar documents
Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

List of Designated High-Cost Drugs

National Cancer Drugs Fund List - Approved

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation

April May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

NB Drug Plans Formulary Update

NBPDP Formulary Update

Quarterly Report on Completed Drug Submission Reviews

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

Prior Authorization Approval Guidelines. May, 2017

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

Biologics for Autoimmune Diseases

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:

ORAL ONCOLOGY CRITERIA

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Cosentyx. Cosentyx (secukinumab) Description

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

Prescription benefit updates Large group

Specialty Pipeline Update

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

ACTEMRA (tocilizumab)

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

Pfizer Pipeline. November 8, 2012

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

Immune Modulating Drugs Prior Authorization Request Form

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

ORAL ONCOLOGY CRITERIA

April 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

CIMZIA (certolizumab pegol)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Cimzia. Cimzia (certolizumab pegol) Description

NICE TA Adherence Check List

Medicare Part C Medical Coverage Policy

Specialty Pipeline Update

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Summary of Strategic Competitive Analysis and Publication Planning

Specialty Pipeline Update

NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

Disclosure. Outline New Info on

Pfizer Pipeline. August 9, 2012

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

JULY 2016 PBAC MEETING POSITIVE RECOMMENDATIONS LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Aetna Better Health. Specialty Drug Program

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Pfizer Pipeline. May 10, 2012

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

NB Drug Plans Formulary Update

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC

March 2017 Pharmacy & Therapeutics Committee Decisions

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target

Pharmacy Services Request Types

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year

Medicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5

Drug Class Review Targeted Immune Modulators

Provider Newsletter. Table of Contents. Reimbursement Policy: Improve member medication regimen. Page 2

Stelara. Stelara (ustekinumab) Description

04 September 2017 Page 1 of 6

03 May 2016 Page 1 of 5. How does the NHS board decide which new medicines to make available for patients?

Keytruda. Keytruda (pembrolizumab) Description

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Pfizer Pipeline. February 28, 2012

Pharmacy and Medical Guideline Updates

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Corporate Medical Policy

I. Diagnosis of the cancer type in CUP

Opdivo. Opdivo (nivolumab) Description

Transcription:

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of March 31, 2018 207 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic Name) Abilify Maintena (aripiprazole long acting injection) Abraxane (nab-paclitaxel) Actemra (tocilizumab) SC Adcetris (brentuximab) Adempas (riociguat) Advair (salmeterol xinafoate/fluticasone propionate) Afinitor (everolimus) Afinitor (everolimus) Alimta (pemetrexed) Anoro Ellipta (umeclidinium bromide/vilanterol trifenatate) Aptiom (eslicarbazepine) Arnuity Ellipta (fluticasone furoate) Aubagio (teriflunomide) Avastin (bevacizumab) Avastin (bevacizumab) Avastin (bevacizumab) Basaglar (insulin glargine) Blincyto (blinatumomab) Bosulif (bosutinib) Botox (onabotulinumtoxin A) Brenzys (etanercept) Breo Ellipta (fluticasone furoate/vilanterol) Breo Ellipta (fluticasone furoate/vilanterol) Brilinta (ticagrelor) Cimzia (certolizumab) Cosentyx (secukinumab) Cosentyx (secukinumab) Cosentyx (secukinumab) Cotellic (cobimetinib) Cyramza (ramucirumab) Daklinza (daclatasvir) Diacomit (stiripentol) Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria Used for the maintenance treatment of schizophrenia Used first-line to treat locally advanced unresectable or metastatic adenocarcinoma of the pancreas Used to treat lymphoma Used to treat chronic thromboembolic pulmonary hypertension and asthma Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer Used to treat neuroendocrine tumours of gastrointestinal or lung origin Used to treat lung cancer (new indication) Used to treat seizures Used to treat asthma Used to treat persistent, recurrent, or metastatic cervical cancer Used to treat epithelial ovarian cancer Used to treat genitourinary platinum-resistant ovarian cancer Used to treat metastatic colorectal cancer Used to treat type 1 and 2 diabetes mellitus Used to treat acute lymphoblastic leukemia Used to treat chronic myelogenous leukemia (CML) Used to treat multiple indications and ankylosing spondylitis Used for the treatment of asthma Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome Used to treat ankylosing spondylitis, psoriatic arthritis Used to treat moderate to severe plaque psoriasis Used to treat psoriatic arthritis Used to treat ankylosing spondylitis Used to treat gastrointestinal metastatic gastric cancer or gastroesophageal junction adenocarcinoma Used to treat chronic Hepatitis C infection Used in patients with severe myoclonic epilepsy in infancy

Dificid (fidaxomicin) Duaklir Genuair (aclidinium bromide/formoterol fumarate dehydrate) Effient (prasugrel) Eliquis (apixaban) Eliquis (apixaban) Entresto (sacubitril/valsartan) Entyvio (vedolizumab) Entyvio (vedolizumab) Epclusa (sofosbuvir/velpatasvir) Erelzi (etanercept) Erivedge (vismodegib) Esbriet (pirfenidone) Esbriet (pirfenidone) Eylea (aflibercept) Eylea (aflibercept) Fabrazyme (agalsidase beta) Fabrazyme (agalsidase beta) Ferriprox (deferiprone) Fibristal (ulipristal acetate) Firazyr (icatibant) Forxiga (dapagliflozin) Galexos (simeprevir) Gazyva (obinutuzumab) Gazyva (obinutuzumab) Genvoya (elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide) Gilenya (fingolimod) Giotrif (afatinib) Giotrif (afatinib) Glatect (glatiramer acetate) * Grastofil (filgrastim) Halaven (eribulin) Harvoni (sofosbuvir/ledipsavir) Harvoni (sofosbuvir/ledipsavir) Holkira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) Humira (adalimumab) Humira (adalimumab) Ibavyr (ribavirin) Used to treat Clostridium difficile (COPD) Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis Used to treat venous thromboembolic events and prevent recurrent deep-vein thrombosis and pulmonary embolism Used to treat heart failure Used to treat ulcerative colitis Used to treat Crohn s disease Used to treat ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis Used to treat metastatic basal cell carcinoma Used to treat idiopathic pulmonary fibrosis Used to treat idiopathic pulmonary fibrosis Used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and/or macular edema secondary to central retinal vein occlusion (CRVO) Used to treat macular edema secondary to branch retinal vein occlusion Used to treat Fabry disease Used to treat Fabry disease Used to treat Transfusional Iron Overload Used to treat uterine fibroids Used to treat acute attacks of hereditary angioedema Used to treat chronic hepatitis C Genotype 1 infection Used to treat chronic lymphocytic leukemia Used to treat follicular lymphoma Used to treat HIV-1 Infection Used to treat advanced non-small cell lung cancer Used to treat advanced non-small cell lung cancer Used for prevention or treatment of neutropenia in various indications Used to treat breast cancer Used to treat ulcerative colitis Used to treat hidradenitis suppurativa

Ibrance (palbociclib) Iclusig (ponatinib) Imbruvica (ibrutinib) Imbruvica (ibrutinib) Imbruvica (ibrutinib) Incruse Ellipta (umeclidinium) Inflectra (infliximab) Inflectra (infliximab) Inlyta (axitinib) Inspiolto Respimat (tiotropium/olodaterol) Inspra (eplerenone) Invega Trinza (paliperidone palmitate) Invokana (canagliflozin) Istodax (romidepsin) Jadenu (deferasirox) Jakavi (ruxolitinib) Jakavi (ruxolitinib) Janumet (sitagliptin/metformin) Januvia (sitagliptin) Jardiance (empagliflozin) Jetrea (ocriplasmin) Kadcyla (trastuzumab emtansine) Kalydeco (ivacaftor) Keytruda (pembrolizumab) Keytruda (pembrolizumab) Keytruda (pembrolizumab) Kuvan (saproterin) Kyprolis (carfilzomib) Kyprolis (carfilzomib) Lemtrada (alemtuzumab) Lenvima (lenvatinib) Lodalis (colesevelam) Mekinist (trametinib) Metadol-D (methadone hydrochloride) Metoject (methotrexate) Mictoryl (propiverine) Mifegymiso (mifepristone/misoprostol) Mozobil (plerixafor) Mozobil (plerixafor) Myrbetriq (mirabegron) Used to treat advanced breast cancer Used to treat Chronic Myeloid Leukemia (CML)/ Acute Lymphoblastic Leukemia Used to treat chronic lymphocytic leukemia or small lymphocytic leukemia Used to treat relapsed/refractory Mantle Cell Lymphoma Used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma (COPD), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis Used to treat ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn s disease and Ulcerative Colitis Used to treat metastatic renal cell carcinoma (COPD) Used to treat New York Heart Association (NYHA) class II systolic heart failure Used to treat schizophrenia Used to treat relapsed/refractory peripheral T-cell lymphoma Used to treat chronic iron overload Used to treat intermediate to high risk myelofibrosis Used to treat polycythemia vera Used to treat symptomatic vitreomacular adhesion Used to treat HER-2 positive metastatic breast cancer Used to treat cystic fibrosis Used to treat non-small cell lung cancer (second line or beyond) Used to treat non-small cell lung cancer (first line) Used to treat phenylketonuria Used to treat multiple myeloma Used to treat multiple myeloma (relapsed) Used to treat thyroid cancer Used to treat hypercholesterolemia Used to treat opioid dependence Used to treat overactive bladder (paediatric) Used for the medical termination of pregnancy Used in combination with granulocyte colony-stimulating factor to support treatment for non-hodgkin lymphoma and multiple myeloma Used in combination with granulocyte colony-stimulating factor to support treatment for non-hodgkin lymphoma and multiple myeloma Used to treat overactive bladder

Narcan (naloxone hydrochloride) Neupro (rotigotine) Nucala (mepolizumab) Ofev (nintedanib) Onbrez (indacaterol) Onglyza (saxagliptan) Oralair (grass pollen allergen extract) Orencia (abatacept) Perjeta (pertuzumab) Pheburane (sodium phenylbutyrate) Plegridy (PegIFN beta-1a) Pomalyst (pomalidomide) Pradaxa (dabigatran) Prezcobix (darunavir/cobicistat) Prolia (denosumab) Ravicti (glycerol phenylbutyrate) Rebif (interferon beta-1a) Remicade (infliximab) Repatha (evolocumab) Replagal (agalsidase alfa) Replagal (agalsidase alfa) Revlimid (lenalidomide) Revlimid (lenalidomide) Rituxan SC (rituximab) Seebri Breezhaler (glycopyrronium bromide) Simbrinza (brinzolamide/brimonidine) Simponi (golimumab) SC Soliris (eculizumab) Sovaldi (sofosbuvir) Sovaldi (sofosbuvir) Spiriva Respimat (tiotropium) Stivarga (regorafenib) Stivarga (regorafenib) Strensiq (asfotase alfa) Stribild (elvitegravir/cobicistat/ emtricitabine/tenofovir) Sunvepra (asunaprevir) Used to treat opioid overdose Used to treat Parkinson's disease Used to treat severe eosinophilic asthma Used to treat idiopathic pulmonary fibrosis Used as a bronchodilator for chronic obstructive pulmonary disease Used to treat advanced or metastatic non-small cell lung cancer Used to treat advanced or metastatic renal cell carcinoma Used to treat squamous cell carcinoma of the head and neck (SCCHN) Used to treat allergic rhinitis with or without conjunctivitis Used to treat breast cancer Used to treat urea cycle disorders (RRMS) Used to treat multiple myeloma Used to prevent strokes in patients with atrial fibrillation Used to treat HIV-1 infection Used to treat osteoporosis Used to treat urea cycle disorders Used for clinically isolated syndrome Used to treat multiple indications including rheumatoid arthritis, ulcerative colitis and Crohn s disease Used to treat primary hyperlipidemia and mixed dyslipidemia Used to treat Fabry Disease Used to treat Fabry Disease Used for maintenance treatment in multiple myeloma after a stem cell transplant Used to treat newly diagnosed multiple myeloma Used to treat multiple indications Used to treat glaucoma and ocular hypertension Used to treat ulcerative colitis Used to treat paroxysmal nocturnal hemoglobinuria Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST) Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST) Used to treat pediatric-onset hypophosphatasia Used to treat HIV-1 infection in antiretroviral treatment-naïve adult patients Used to treat chronic Hepatitis C

Sutent (sunitinib) Sylvant (siltuximab) Tafinlar (darafenib) Tafinlar (dabrafenib) and Mekinist (tramatinib) Taltz (Ixekizumab) Tecfidera (dimethyl fumarate) Tivicay (dolutegravir) Tobi Podhaler (tobramycin) Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin) Treanda (bendamustine) Triumeq (dolutegravir/abacavir/lamivudine) Tudorza Genuair (aclidinium bromide) Tysabri (natalizumab) Ultibro (indacaterol/glycopyrronium) Uptravi (selexipag) Valtrex (valacyclovir) Vectibix (panitumumab) Vosevi (sofosbuvir velpatasvir voxilaprevir) Votrient (pazopanib) Votrient (pazopanib) Xalkori (crizotinib) Xalkori (crizotinib) Xarelto (rivaroxaban) Xarelto (rivaroxaban) Xeljanz (tofacitinib) XigDuo (dapagliflozin/metformin hydrochloride) Xolair (omalizumab) Xtandi (enzalutamide) Xtandi (enzulatamide) Yervoy (ipilimumab) Yervoy (ipilimumab) Zaxine (rifaximin) Used to treat pancreatic neuroendocrine tumours Used to treat multicentric Castleman s disease (in combination) Used to treat moderate to severe plaque psoriasis Used to treat multiple sclerosis Used to treat HIV-1 infection Used for the management of cystic fibrosis patients with chronic pulmonary Pseuodomonas aeruginosa infections Used to treat non-hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia Used to treat HIV-1 infection Used in management of chronic obstructive pulmonary disease (COPD) Used to treat pulmonary arterial hypertension Used to treat specific viral infections Used to treat metastatic colorectal cancer Used to treat metastatic renal cell carcinoma Used to treat metastatic renal cell carcinoma Used to treat advanced non-small cell lung cancer (second-line) Used to treat advanced non-small cell lung cancer (first-line) New indication for treatment of venous thromboembolic events and prevention of recurrent deep vein thrombosis and pulmonary embolism. Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis Used to treat type 2 diabetes mellitus Used to treat chronic idiopathic urticaria Used to treat first-line metastatic castrate resistant prostate cancer (before chemotherapy) Used to treat castrate resistant prostate cancer (after chemotherapy) Used for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma Used for the second-line treatment of adult patients with unresectable or metastatic melanoma Used to treat hepatic encephalopathy Zepatier (elbasvir grazoprevir) Used for the treatment of Hepatitis C (genotype 1, 4) Zydelig (idelalisib) Zykadia (ceritinib) * Zytiga (abiraterone) Used to treat relapsed chronic lymphocytic leukemia (CLL) Used to treat ALK+ non-small cell lung cancer Used to treat prostate cancer

22 drug negotiations were closed as agreements were not reached: Abilify (aripiprazole) Adempas (riociguat) Brilinta (ticagrelor) Butrans (buprenorphine) Byetta (exenatide) Campral (acamprosate calcium) Caprelsa (vandetanib) Daklinza (daclatasvir) Invokamet (canagliflozin/metformin hydrochloride) Kalydeco (ivacaftor) Kevzara (sarilumab) Methadose (methadone) Mictoryl (propiverine) Opsumit (macitentan) Otezla (apremilast) Otezla (apremilast) Rosiver (ivermectin) Simponi (golimumab) IV Soliris (eculizumab) Strensiq (asfotase alfa) Technivie (ombitasvir/paritaprevir/ ritonavir) Victoza (liraglutide) Used for the treatment of schizophrenia and related psychotic disorders Used to treat pulmonary arterial hypertension Used with ASA to prevent atherothrombotic events with history of myocardial infarction Used to treat persistent pain of moderate intensity Used for maintenance of alcohol abstinence Used to treat medullary thyroid cancer Used to treat chronic Hepatitis C Used to treat type 2 diabetes mellitus Used to treat cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation Used to treat opioid dependence Used to treat overactive bladder Used to treat pulmonary arterial hypertension Used to treat moderate to severe plaque psoriasis Used to treat psoriatic arthritis Used to treat rosacea Used to treat ahus Used to treat hypophosphatasia Used for the treatment of Hepatitis C (genotype 4) ** A completed pan-canadian negotiation refers to those for which a Letter of Intent (document which outlines the agreed upon terms and conditions for listing) has been signed between the lead jurisdiction for the negotiation and the manufacturer OR negotiations have been closed without a Letter of Intent. The initial nine products negotiated through the pcpa. * New negotiations completed since last update of February 28, 2018. www.canadaspremiers.ca